Atai Life Sciences’ Drug Trial For Depression Fails To Deliver Expected Results, Stock Plunges
© Courtesy of Benzinga New York-based Perception Neuroscience, the clinical-stage psychedelic biotechnology company Atai Life Sciences (NASDAQ: ATAI ), announced the results of its PCN-101 study of a specific R-ketamine in patients with treatment-resistant depression (TRD). Although the combination showed signs of efficacy at all time points, the study did not reach the primary endpoint … Read more